Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expressing Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00095537
What this trial is testing

BMS-599626 in Patients With Advanced Solid Malignancies

Who this might be right for
CancerMetastases
Bristol-Myers Squibb 60
Early research (Phase 1)Looking for participantsNCT06293898
What this trial is testing

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Who this might be right for
Endometrial CancerCervical CancerOvarian Cancer+7 more
SystImmune Inc. 280
Large-scale testing (Phase 3)Looking for participantsNCT06504732
What this trial is testing

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

Who this might be right for
Stomach NeoplasmsSolid Tumor
SUNHO（China）BioPharmaceutical CO., Ltd. 574
Early research (Phase 1)UnknownNCT03847168
What this trial is testing

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Who this might be right for
Breast CancerGastric/Gastroesophageal Junction Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 22
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Early research (Phase 1)Ended earlyNCT02829372
What this trial is testing

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

Who this might be right for
HER2 Expressing Solid Tumours
Ichnos Sciences SA 36
Early research (Phase 1)Looking for participantsNCT07334119
What this trial is testing

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-Expressing Solid Tumors
Myeloid Therapeutics 60
Testing effectiveness (Phase 2)Looking for participantsNCT07617805
What this trial is testing

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Who this might be right for
Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech 42
Early research (Phase 1)Study completedNCT01730118
What this trial is testing

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Who this might be right for
Breast NeoplasmsBreast CancerAdenocarcinomas+1 more
National Cancer Institute (NCI) 33
Early research (Phase 1)Study completedNCT02576548
What this trial is testing

MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

Who this might be right for
HER2 Expressing Breast or Gastric/Stomach Cancers
MedImmune LLC 47
Early research (Phase 1)Active Not RecruitingNCT04294628
What this trial is testing

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI) 62
Early research (Phase 1)UnknownNCT06154343
What this trial is testing

GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd. 150
Early research (Phase 1)UnknownNCT05819684
What this trial is testing

SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 133
Early research (Phase 1)WithdrawnNCT06560138
What this trial is testing

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

Who this might be right for
HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
Atridia Pty Ltd.
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Early research (Phase 1)Study completedNCT02276300
What this trial is testing

HER2-Peptide Vaccination of Patients With Solid Tumors

Who this might be right for
Gastric CancerBreast Cancer
Technical University of Munich 2
Early research (Phase 1)Looking for participantsNCT05861895
What this trial is testing

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

Who this might be right for
Solid Tumors, Adult
HighField Biopharmaceuticals Corporation 84
Early research (Phase 1)Study completedNCT04446260
What this trial is testing

SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 396
Testing effectiveness (Phase 2)Active Not RecruitingNCT06271837
What this trial is testing

T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Who this might be right for
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
AstraZeneca 127
Next Page